



Innovative Cell and Tissue Technology

Press release
January 26, 2009
Gothenburg, Sweden

Presentation of Vitrolife for the benefit of MediCult's shareholders

Vitrolife AB (publ) ("Vitrolife") invites the shareholders of MediCult a/s ("MediCult") (OSE: MEC) to attend a presentation by Vitrolife's CEO, Magnus Nilsson.

On Wednesday 28 January 2009 at 12.00 CET, Mr. Nilsson will give a presentation of Vitrolife and its products for the benefit of the shareholders of MediCult. In addition, Mr. Nilsson will give his views on the proposed combination of Vitrolife and MediCult. Refreshments will be served.

Location:

Carnegie Conference Centre, Stranden 1B, 3.etg, Oslo.

Please email ah@carnegie.no if you are interested in attending the presentation.

Queries should be addressed to:

Anita Ahlqvist, CEO Assistant, phone +46 31 721 80 83

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation.

The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body in order to select usable organs and keeping them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 150 employees and its products are sold in more than 80 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France and Italy. Production facilities are located in Sweden and the USA.

The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com. Homepage: www.vitrolife.com.